Improving bladder cancer detection with artificial intelligence
Official title: Augmented Bladder Tumor Detection Using the Bladder-Portable Artifact Detection System: A Multicentric Prospective Analytic Study Using Real Time Based Artificial Intelligence (IA).
Run by Centre Hospitalier Universitaire, Amiens · NCT05415631 · Data updated 2026-11-12
This study is testing whether using artificial intelligence during bladder exams can help doctors find tumors more accurately and improve treatment for patients with bladder cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | May 13, 2022 |
| Main results expected | May 2027 |
| Study ends | May 2029 |
| Registry record updated | July 15, 2022 |
| Trial ID | NCT05415631 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with unifocal or multifocal primary or recurrent bladder cancer that meets specific size and number criteria.
✕Probably not a fit
Patients with advanced bladder cancer, evidence of distant metastases, or those who have recently undergone certain treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to enhance the diagnosis and monitoring of bladder tumors by integrating artificial intelligence with standard bladder endoscopy. The primary goal is to reduce diagnostic errors and improve the accuracy of tumor mapping, while also standardizing the descriptive analysis of lesions. By utilizing AI, the study seeks to better characterize tumor aggressiveness and develop a new precision diagnostic tool to improve therapeutic management of bladder cancer. The approach focuses on patients with specific criteria related to tumor size and number.
Why it matters
Potential benefit: If successful, this study could significantly improve the accuracy of bladder cancer diagnoses, leading to better patient outcomes.
How similar studies have gone: Other studies have shown promise in using artificial intelligence for diagnostic purposes, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm * multifocal primary or recurrent suspected bladder cancer less or equal than 5 lesions and with tumor size less or equal than 3 cm. Exclusion Criteria: * Evidence of more than 5 tumors or more than 3 cm * computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher) * computed tomography/magnetic resonance evidence of distant metastases (lymphatic or organic) * Exclusion criteria will include gross hematuria and bacillus Calmette-Guerin (BCG) treatment or chemotherapy within 3 months of inclusion * An exception will be made if patients had received only a single course of chemotherapy immediately following TUR * Patients objecting to the use of their data in the context of research.
Where it's running
-
Amiens University Hospital
Amiens, France Recruiting
Study contacts
- Study coordinator: Fabien SAINT, Pr
- Email: saint.fabien@chu-amiens.fr
- Phone: 03 22 45 59 45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy
This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.
-
Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion
This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.
-
Personalized 3D Tumoroids from Your Tumor to Test Treatments
Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.